| Title |
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2015
|
| DOI | 10.2147/dddt.s69433 |
| Pubmed ID | |
| Authors |
Alejo Rodriguez-Vida, Myria Galazi, Sarah Rudman, Simon Chowdhury, Cora N Sternberg |
| Abstract |
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of administering them. Enzalutamide is a nonsteroidal second-generation antiandrogen that has been approved for the treatment of metastatic CRPC both in the post-docetaxel and chemotherapy-naïve settings. This article reviews the pharmacological characteristics of enzalutamide, the efficacy studies which led to its approval, its safety profile, and quality of life-related parameters as well as its place in the sequential treatment and management of metastatic prostate cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 1% |
| Unknown | 90 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 19% |
| Researcher | 14 | 15% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Master | 8 | 9% |
| Student > Doctoral Student | 6 | 7% |
| Other | 12 | 13% |
| Unknown | 21 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 27% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Agricultural and Biological Sciences | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Computer Science | 2 | 2% |
| Other | 11 | 12% |
| Unknown | 28 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2023.
All research outputs
#5,393,063
of 25,837,817 outputs
Outputs from Drug Design, Development and Therapy
#358
of 2,285 outputs
Outputs of similar age
#62,438
of 284,421 outputs
Outputs of similar age from Drug Design, Development and Therapy
#15
of 126 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 126 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.